Low Total Dose of Anti-Human T-Lymphocyte Globulin (ATG) Guarantees a Good Glomerular Filtration Rate after Liver Transplant in Recipients with Pretransplant Renal Dysfunction
Table 1
Patient characteristics and surgical data.
ATG Group (n=20)
BAS group (n=20)
p-value
Age (years)
60(±6)
57 (±7)
0.143
Male, n (%)
18 (90%)
17 (85%)
1
Primary liver disease
0.215
Alcoholic
11 (55%)
11(55%)
Hepatitis C
4 (20%)
8 (40%)
HCC
3 (15%)
1 (5%)
Hepatitis B
1 (5%)
-
NASH
1 (5%)
-
Pre-LT Arterial Hypertension, n (%)
6 (30%)
5 (25%)
0.723
Pre-LT Diabetes Mellitus, n (%)
10 (50%)
4 (20%)
0.096
Pre-LT Cardiologic Disease, n(%)
4 (20%)
-
0.106
Median pre-eGFR (mL/min/1.73m2)
49±9
34±12
0.001
MELD score
20 (±7)
26 (±9)
0.065
Cold ischemia time (min)
325±85
370±96
0.070
Warm ischemia time (min)
45±19
39±10
0.254
Intraoperative transfusion
Red blood cells (Unit)
5 (0-26)
6 (4-11)
0.060
Fresh Frozen Plasma (Unit)
2 (0-18)
8 (0-16)
0.003
Platelets (Unit)
0 (0-10)
2 (0-20)
0.068
Piggy-back with portacaval shunt
11 (55%)
17 (85%)
0.082
Hospital Stay (days)
20 (11-90)
15 (10-114)
0.242
NASH, nonalcoholic steatohepatitis; eGFR, estimated glomerular filtration rate, and MELD; model for end-stage liver disease.
